Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Posted by Francis Steltz on Jul 31st, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) saw a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 55,656 shares, a decline of 32.1% from the June 30th total of 82,016 shares. Based on an average trading volume of 117,234 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.4% of the shares of the stock are sold short.

Insider Buying and Selling at Cadrenal Therapeutics

In other news, CEO Quang X. Pham sold 12,996 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $3.94, for a total value of $51,204.24. Following the sale, the chief executive officer directly owned 136,381 shares in the company, valued at $537,341.14. This represents a 8.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 97,500 shares of company stock valued at $388,290 over the last ninety days. Insiders own 26.09% of the company’s stock.

Institutional Investors Weigh In On Cadrenal Therapeutics

Several hedge funds have recently modified their holdings of CVKD. DRW Securities LLC acquired a new position in Cadrenal Therapeutics during the fourth quarter worth approximately $171,000. Citadel Advisors LLC acquired a new position in shares of Cadrenal Therapeutics in the 3rd quarter valued at $274,000. JPMorgan Chase & Co. purchased a new stake in shares of Cadrenal Therapeutics during the 3rd quarter valued at $103,000. Finally, Geode Capital Management LLC grew its stake in shares of Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the period. 7.92% of the stock is owned by institutional investors and hedge funds.

Cadrenal Therapeutics Stock Up 6.1%

Shares of NASDAQ:CVKD opened at $2.09 on Friday. The company has a market cap of $7.15 million, a P/E ratio of -0.37 and a beta of 1.73. The business has a fifty day simple moving average of $3.33 and a 200-day simple moving average of $5.26. Cadrenal Therapeutics has a 52 week low of $1.86 and a 52 week high of $14.64.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.47. Sell-side analysts expect that Cadrenal Therapeutics will post -4.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on CVKD shares. Wall Street Zen raised shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright lowered their price target on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cadrenal Therapeutics has an average rating of “Hold” and a consensus target price of $13.00.

View Our Latest Research Report on CVKD

About Cadrenal Therapeutics

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.